Skip to main content
. 2010 Jun 1;69(6):1158–1161. doi: 10.1136/ard.2009.119222

Figure 2.

Figure 2

(A) Proportion of patients not progressing over the duration of the study. (B) Proportion of patients with no new erosions over the duration of the study. (C) Treatment effect of placebo plus MTX and rituximab (2 × 1000 mg) plus MTX on total Genant–modified Sharp score. (D) Annualised rate of progression in total Genant–modified Sharp score. BL, baseline; MTX, methotrexate *p<0.005; **p<0.0001.